ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 458 • 2016 ACR/ARHP Annual Meeting

    The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis

    Claire E.J. Waterborg1, Paqui G. Través2, Silke Beermann1, Marije I. Koenders1, Greg Lemke2 and Fons A.J. van de Loo1, 1Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, 2Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA

    Background/Purpose:  Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an unrestrained inflammatory response in selective, anatomically distinct synovial joints. The innate immune system…
  • Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting

    Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis

    Juan Jiao1, Hai-bo Yin2, Xiao-po Tang2, Xun Gong2 and Quan Jiang1, 1Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    Background/Purpose:  Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
  • Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting

    TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models

    Yohei Yoshiga1, Fumihito Hosoi1, Satoru Iguchi1, Ryuusuke Kaneko1, Yoshinori Nakachi1, Daichi Akasaka1, Kenji Tanaka2, Kazuhiko Yonekura2, Teruhiro Utsugi2, Eiji Sasaki2 and Yoshikazu Iwasawa2, 1TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, 2TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

    Background/Purpose:  Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…
  • Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting

    Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country

    Liliana Uribe Botero1, Margarita A Saldarriaga Alvarez1, Natalia Duque Zapata1, Johnny Urrego1, Oscar Jair Felipe Diaz1, Carmen Cerón2, Alejandro Uribe1, Luis Alonso Gonzalez1,3 and José A. Gómez-Puerta1, 1Medicarte IPS, Medellín, Colombia, Medellín, Colombia, 2Medicarte IPS, Medellín, Colombia, 3Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia

    Background/Purpose:  Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
  • Abstract Number: 485 • 2016 ACR/ARHP Annual Meeting

    Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis

    Emily Wu1, Richard Bell2, Christopher Rudmann3, Ronald Wood4, Christopher T. Ritchlin5, Homaira Rahimi6 and Edward Schwarz7, 1Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 2Pathology, University of Rochester, Rochester, NY, 3Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, 4University of Rochester, Rochester, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, 7Orthopedeatrics, University of Rochester, Rochester, NY

    Background/Purpose: Although rheumatoid arthritis (RA) tends to occur earlier and with increased severity in females, the underling etiology of this sexual dimorphism is unknown. We…
  • Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting

    Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study

    Alfons A. den Broeder1, Chantal A.M. Bouman1, Frank H.J. van den Hoogen1,2, Jaap Fransen2, Ronald F. van Vollenhoven3, Johannes W.J. Bijlsma4, Aatke van der Maas1 and Noortje van Herwaarden1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…
  • Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting

    The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis

    Josef Smolen1, Roy Fleischmann2, Daniel Aletaha3, Yihan Li4, Stefan Florentinus4 and Ivan Lagunes Galindo4, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 3Medical University Vienna and Hietzing Hospital, Vienna, Austria, 4AbbVie Inc., North Chicago, IL

                                                                                                                           Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…
  • Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting

    The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study

    Sheng-Xiao Zhang1, Miao Miao2, Xiao-Qing Liu2, Xiao-Wen Ma2, Xiao-Yan Wu2 and Xiao-Feng Li1, 1Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China

    Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
  • Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting

    Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients

    Fadil Pirbuccus1, Christine Galant1, Adrien Nzeusseu Toukap2, Frédéric A. Houssiau1, Patrick Durez2 and Bernard R. Lauwerys1, 1Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose:  Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
  • Abstract Number: 3124 • 2016 ACR/ARHP Annual Meeting

    Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene

    Teresina Laragione1, Percio Gulko1 and Max Brenner2, 1Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose:  Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but…
  • Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting

    Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort

    Jeffrey A. Sparks1, Shun-Chiao Chang2, Kevin D. Deane3, Ryan W. Gan4, Kristen Demoruelle3, Marie L. Feser3, LauraKay Moss3, Jane H. Buckner5, Richard M. Keating6, Karen H. Costenbader7, Peter K. Gregersen8, Michael H. Weisman9, Ted R. Mikuls10, James R. O'Dell10, V. Michael Holers3, Jill M. Norris4 and Elizabeth W. Karlson2, 1Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Epidemiology, Colorado School of Public Health, Aurora, CO, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Division of Rheumatology, Scripps Health, La Jolla, CA, 7Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 8Feinstein Insititute for Medical Research, Manhasset, NY, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
  • Abstract Number: 2582 • 2015 ACR/ARHP Annual Meeting

    Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice

    Richard Bell1, Ronald Wood2, Joe Chakkalakal3, Christopher T. Ritchlin4, Edward Schwarz5 and Homaira Rahimi6, 1Pathology, University of Rochester, Rochester, NY, 2University of Rochester, Rochester, NY, 3Orthopaedics, University of Rochester, Rochester, NY, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Orthopedeatrics, University of Rochester, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic debilitating condition with a 2-3 fold greater prevalence in women than men. Additionally, women have worse disease outcomes…
  • Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting

    Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis

    Jing Yao Leong1,2, Raymond Ong Jr.3, Juntao Li4, Theodorus van den Broek5, Roberto Spreafico4, Maura Rossetti1 and Salvatore Albani1,2, 1SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, 2Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, 3Singhealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 4SingHealth Translational Immunology and Inflammation Centre (STIIC), Singapore Health Services Pte Ltd, Singapore, Singapore, 5Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA

    Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…
  • Abstract Number: 2704 • 2015 ACR/ARHP Annual Meeting

    Neutrophil-Derived Lactoferrin Regulates the Activity of NFAT5 in Rheumatoid Arthritis Synovial Fibroblasts Via Toll-like Receptor 4

    Kunihiko Umekita, Shunichi Miyauchi, Kazuyoshi Kubo, Hajime Nomura, Kazumi Umeki, Koushou Iwao, Mao Komura and Akihiko Okayama, Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan

    Background/Purpose: Damage-associated molecular patterns (DAMPs) are proposed to drive aberrant stimulation of Toll-like receptors (TLRs) in the rheumatoid arthritis (RA) joints resulting in increased expression…
  • Abstract Number: 1586 • 2015 ACR/ARHP Annual Meeting

    Weight Loss in Obese Rheumatoid Arthritis (RA) Patients Improves Disease Activity without Modifying RA Treatment

    Elisa Gremese1, Maria Rita Gigante1, Barbara Tolusso1, Anna Laura Fedele1, Silvia Canestri1, Barbara Aquilanti2, Clara Di Mario1, Luca Petricca1, Stefano Alivernini1 and Gianfranco Ferraccioli1, 1Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 2Dietology Service, Association Columbus, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Obesity is recognized as a systemic, low-grade inflammatory state and the adipose tissue as an endocrine organ releasing pro-inflammatory cytokines. On the other hand,…
  • « Previous Page
  • 1
  • …
  • 204
  • 205
  • 206
  • 207
  • 208
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology